Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C.
Chi SN, Yi JS, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey BD, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Ramirez NC, Jaju A, Mhlanga JC, Fox E, Hawkins DS, Mooney MM, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW. Chi SN, et al. Among authors: mhlanga jc. J Natl Cancer Inst. 2023 Nov 8;115(11):1355-1363. doi: 10.1093/jnci/djad085. J Natl Cancer Inst. 2023. PMID: 37228094 Free PMC article.
Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D.
Laetsch TW, Ludwig K, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey B, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Mhlanga J, Fox E, Weigel BJ, Hawkins DS, Mooney MM, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW. Laetsch TW, et al. JCO Precis Oncol. 2024 Sep;8:e2400258. doi: 10.1200/PO.24.00258. JCO Precis Oncol. 2024. PMID: 39298693 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 39112380
FDG-PET/CT response assessment with qualitative Lugano criteria outperforms change in SUVmax as a predictive biomarker in frontline treatment of mantle cell lymphoma.
Russler-Germain DA, Calhoun BR, Wu N, Watkins MP, Siegel BA, Bartlett NL, Mhlanga JC. Russler-Germain DA, et al. Among authors: mhlanga jc. Leuk Lymphoma. 2023 Nov-Dec;64(11):1870-1874. doi: 10.1080/10428194.2023.2239404. Epub 2023 Jul 25. Leuk Lymphoma. 2023. PMID: 37489928 No abstract available.
Added Value of FDG PET/MRI in Gynecologic Oncology: A Pictorial Review.
Tarcha Z, Konstantinoff KS, Ince S, Fraum TJ, Sadowski EA, Bhosale PR, Derenoncourt PR, Zulfiqar M, Shetty AS, Ponisio MR, Mhlanga JC, Itani M. Tarcha Z, et al. Among authors: mhlanga jc. Radiographics. 2023 Aug;43(8):e230006. doi: 10.1148/rg.230006. Radiographics. 2023. PMID: 37410624 Review.
Importance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy.
Hoppe BS, McCarten KM, Pei Q, Kessel S, Alazraki A, Mhlanga JC, Lai HA, Eutsler E, Hodgson DC, Roberts KB, Charpentier AM, Keller FG, Voss SD, Wu Y, Cho SY, Kelly KM, Castellino SM. Hoppe BS, et al. Among authors: mhlanga jc. Int J Radiat Oncol Biol Phys. 2023 Aug 1;116(5):1025-1030. doi: 10.1016/j.ijrobp.2023.02.020. Epub 2023 Mar 2. Int J Radiat Oncol Biol Phys. 2023. PMID: 36868525 Free PMC article.
23 results